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Abstract
HIV-1 sequences are highly diverse due to the inaccuracy of the viral reverse transcriptase. This diversity has been studied and used to
categorize HIV isolates into subtypes or clades, which are geographically distinct. To develop effective vaccines against HIV-1,
immunogens representing different subtypes may be important for induction of cross-protective immunity, but little data exist describing
and comparing the immunogenicity induced by different subtype-based vaccines. This issue is further complicated by poor expression of
HIV structural antigens due to rev dependence. One costly approach is to codon optimize each subtype construct to be examined.
Interestingly, cis-acting transcriptional elements (CTE) can also by pass rev restriction by a rev independent export pathway. We reasoned
that revCTE constructs might have advantages for such expression studies. A subtype A envelope sequence from a viral isolate from east
Africa was cloned into a eukaryotic expression vector under the control of the CMV-IE promoter. The utility of inclusion of the
Mason–Pfizer monkey virus (MPV)-CTE with/without rev for driving envelope expression and immunogenicity was examined. Expression
of envelope (gp120) was confirmed by immunoblot analysis and by pseudotype virus infectivity assays. The presence of rev and the CTE
together increased envelope expression and viral infection. Furthermore the CTErev construct was significantly more immunogenic then
CTE alone vector. Isotype analysis and cytokine profiles showed strong Th1 response in plasmid-immunized mice, which also demonstrated
the superior nature of the revCTE construct. These responses were of similar or greater magnitude to a codon-optimized construct. The
resulting cellular immune responses were highly cross-reactive with a HIV-1 envelope subtype B antigen. This study suggests a simple
strategy for improving the expression and immunogenicity of HIV subtype-specific envelope antigens as plasmid or vector-borne
immunogens.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The Human immunodeficiency virus (HIV) is spreading
rapidly throughout the developing world. In particular in
Africa nearly 7% of the adults in 21 different countries are
estimated to be HIV infected. Furthermore nearly 20% in
South Africa and up to 50% of people in Botswana are
reported to be infected (Cohen, 2000a). AIDS is responsible
for 40% of the deaths in sub-Saharan Africa and within the
next 10 years it is estimated to account for more than twice
the number of deaths due to all other causes combined
(Cohen, 2000b). In light of their already overburdened
health system, complex politics and leadership, and insuf-
ficient financial resources, the 22.5 million people living
with HIV/AIDS in Africa face a grim outlook. Recently
great strides were made in the public sector to try to raise
the enormous sums necessary to support HIV treatment
protocols for Africa. However, as this is not a cure, cur-
rently it represents an important humanitarian stop-gap
measure that is unlikely to stop the spread of HIV infection.
This situation can be expected to worsen unless increased
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research efforts can produce an effective vaccine (Cohen,
2000a,b,c; UNAIDS, 2000).
The diverse genotypes of HIV-1 raise the possibility that
there are functional and biological differences among the
multiple HIV subtypes reported (Kanki et al., 1999; Nabel
et al., 2002; Gaschen et al., 2002; Hoelscher et al., 2002).
Some studies have suggested differences in disease progres-
sion between non-A and A subtypes (Saphire et al., 2001).
Furthermore the problem of developing broadly cross-reac-
tive antibody and cellular immune responses is unsolved
(Rytting et al., 2000; Saphire et al., 2001; Barouch et al.,
2002). Therefore, any vaccine produced may need to be
tailored in some fashion to protect against regional viruses
or a wide variety of subtypes. Having a large collection of
subtype-unique antigens would aid the study of this issue.
For this purpose DNA vaccines are an appropriate approach
for studying subtype immunity as they can be designed to
include multiple HIV subtypes (MacGregor et al., 2002;
Gaschen et al., 2002). This is especially relevant for Africa
where subtype C plagues much of sub- Saharan Africa
(Cohen, 2000 a,b), while subtype A affects the majority of
east and west Africa (Kanki et al., 1999), in addition sub-
types D and B are also widespread. Epidemiological studies
have shown that the majority of east and west Africa,
including Uganda and the city of Abidjan in Cote d’Ivoire,
is subtype A endemic and suffers HIV/AIDS adult preva-
lence’s rates and related deaths that are among the highest
on the African continent (Kanki et al., 1999; Nasioulas et
al., 1999; Cohen, 2000a,b; Ndung’u and Lu, 2001; Gaschen
et al., 2002).
DNA immunization for HIV-1 is a new technique in
vaccine development (Wang et al., 1993; Amara et al.,
2001; Nabel et al., 2002). In this delivery system, antigens
are synthesized within host cells including professional
APCs, where the antigens can be processed and presented
through the MHC-1 pathway to activate specific CD8 T-
lymphocytes (Chattergoon et al., 1998). However, one
drawback with the plasmid approach for HIV is currently
the lack of potent envelope immunogens. It is important to
produce high expressing vectors to develop more potent
immune responses. To achieve this end codon changes have
been suggested to enhance expression of HIV antigens for
DNA vaccines (Hass et al., 1996; Tabernero et al., 1996;
Nappi et al., 2001; Muthumani et al., 2002a; zur Megede et
al., 2002). However this process can be complicated, and it
is frequently difficult to assemble antigens especially for
larger gene sequences. Furthermore, while codon optimiza-
tion produces much higher expression of Gag and Pol an-
tigen, the immunogenicity of envelope cassettes has largely
been disappointing. Therefore it would be a significant
advantage for the screening phase if a quicker and simple
strategy existed for rapidly developing HIV envelope im-
munization cassettes. This would be particularly advanta-
geous for allowing analysis of different subtype envelope
responses in a straightforward manner.
The HIV-1 genome consists of the gag, pol, and env
genes, common with all members of the retrovirus family,
as well as six accessories genes tat, vpr, vpu, nef, rev, and
vif (Nasioulas et al., 1999; Frankel and Young, 1998). While
most HIV-1 gene products in theory could be potential
vaccine target antigens, the viral envelope is particularly
important as it is the only target antigen for the generation
of neutralizing antibodies. Therefore, it is especially impor-
tant to develop and study vaccines which target the gp160
antigen (Pfeiffer et al., 1997; Burton and Parren, 2000;
Dimitrov et al., 2001).
Previously, our laboratory has reported on a subtype B
envelope based DNA vaccine (Wang et al., 1993; Boyer et
al., 1997). For these constructs, expression was driven by
the rev response element only. We also previously reported
on gag vectors driven by cis- acting transactivation element
(CTE) alone (Boyer et al., 1997; Muthumani et al., 2002).
Several laboratories have studied CTEs as they allow trans-
port of viral mRNA with some efficiency to the rough
endoplasmic reticulum (RER) (Schwartz et al., 1992; Nappi
et al., 2001; Muthumani et al., 2002a). The combination of
CTEs and rev together has not been previously studied. In
this article, we report the construction of plasmids express-
ing a subtype A envelope from east Africa. This envelope is
driven by a Mason–Pfizer monkey virus (MPV)-CTE with
(EAC-I) or without (EAC-II) the rev element. We observed
the inclusion of this CTE element with rev-enhanced ex-
pression in vitro. Furthermore, double export vector or con-
structing the combination of CTE and rev generated signif-
icantly improved anti-env immunity in vivo. These
constructs should be useful to study cross-clade immuno-
genicity of this and other subtype A vaccines from east
Africa. Furthermore, this appears to be a rapid and simple
approach for the study and development of envelope-spe-
cific immunogens.
Results
Construction and expression of EAC-I and EAC-II env
genes
HIV-1 subtype A containing plasmids in a prokaryotic
cloning vector were obtained from Walter Reed Institute,
MD. The dj264 isolate, was determined based on sequence
to be of interested for further study. It is characterized as an
east African isolate based in part on sequence homologies
shown in Fig. 1 as described (Hoelscher et al., 2002). A
DNA vaccine cassette was constructed by cloning the full-
length HIV-1 envelope protein sequence from this subtype
A clone with or without rev. A PCR template encoding the
rev start site through gp160 and ending at the end of the 3
rev open reading frame (ORF) was ligated into the
pCDNA3.1 plasmid. The resultant plasmids EAC-I with
CTE and rev and EAC-II without rev were confirmed by
sequencing (Figs. 2A and B). We compared the sequence
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with the amino acid sequence of an envelope subtype B
(JR-FL) encoding a codon-optimized envelope that lacks
rev or CTE. JR-FL and the EAC-I inserts are 94% identical
and are shown in Fig. 2C. To test whether the new con-
structs were functional, total proteins were extracted after
transfection and immunoblotted with an anti-HIV-1 gp120
monoclonal antibody (ID6) that is highly cross-reactive
(Dickey et al., 2000). As shown in Fig. 3A, both EAC-I and
EAC-II constructs expressed a detectable envelope pro-
tein (gp120). However, expression of EAC-I appears
more potent than EAC-II. There appears to be an impor-
tant effect of the CTE elements in the context of rev for
improving plasmid expression. It is of particular interest
that the CTE and rev dual constructs expression appeared
as high as the codon optimized envelope subtype B con-
struct.
To further study the expression of these full-length en-
velope constructs, and to test whether the expressed enve-
lope protein was functional during infection, we generated
pseudotyped viral particles by cotransfecting cells with the
proviral DNA -pNL4-3/E construct (envelope negative)
and either EAC-I or EAC-II or a control pNL4-3 wild-type
expression plasmid. One advantage of cloning the full-
length native gp160 driven by rev and a CTE should be the
maintenance of the functional env phenotype. The plasmid
was used as a positive control and the vector backbone was
used as a negative control in this assay. Forty-eight hours
after transfection, supernatants containing viral particles
were collected and filtered with a 0.2-m filter to remove
cell contaminants. For infection we used a concentration of
100 TCID50/106 cells/ml to infect normal human PBMCs.
Six hours after infection, the cells were washed and incu-
bated in fresh RPMI with 10% FBS.
Ninety-six hours hours postinfection, -the supernatants
were tested for p24Gag production by ELISA (Fig. 3B). The
p24Gag production was high in EAC-1. Furthermore, the
infected PBMCs were stained intracellularly to follow in-
fection with an antibody against p24Gag. Samples were then
analyzed by FACS analysis (Fig. 3C). In this assay the
increased infection of EAC-1 over EAC-II is evident. These
results confirm that EAC-I and EAC-II envelopes are func-
tional. The data also illustrate that the presence of CTE 
rev and the increased expression levels and has an effect on
functional envelope expression. It also appears that the CTE
alone construct (EAC-II) was capable of producing infec-
tious virus. Based on these encouraging results, we next
compared the effects of the CTE  rev expression vs the
other constructs in plasmid vaccination experiments.
Fig. 1. Phylogenetic tree of HIV-1 envelope subtype A. The arrow indicates the selection of protetypic African subtype A (east African subtype: 02AG FR91
DJ264).
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Humoral response induction
To determine whether the EAC-I and EAC-II plasmids
will elicit different levels of humoral and cellular immune
responses as plasmid vaccines, mice were immunized with
each plasmid or vector control or a codon-optimized JR-FL
as a positive control and the resulting immune responses
were analyzed. Mice in each group were injected three times
(weeks 0, 2, and 4), a prime and two booster injections, with
100 g of each plasmid DNA. Sera from immunized mice
were collected 1 week after the second booster injection and
analyzed for envelope-specific serum antibody by Western
blot analysis as described under Materials and methods.
Commercial envelope subtype B Western blot strips were
incubated with immune sera from EAC-I, EAC-II, or enve-
lope subtype B (JR-FL) vaccinated animals (Fig. 4A). Of
note, the level of envelope-specific antibody response ap-
pears most potent in EAC-I and is comparable to optimized
plasmid immunized animals.
Sera were also analyzed for specific antibody responses
against envelope by ELISA. Fig. 4B shows the envelope-
specific antibody responses from sera collected at weeks 0,
2, 4, and 6. In all groups, antibodies were readily detectable
at a dilution of 1:100. However, we observed the highest
level of antibody responses with sera from the EAC-I-
injected animals. Our data show that EAC-I induced a
higher titer of antibody than EAC-II, and the antibody titers
were equivalent to the optimized subtype B derived enve-
lope. In contrast, the vector alone mice did not develop
specific antibody responses. As antibody response is only
one measurement of immunity, we next examined the in-
duced cellular immune responses.
Fig. 2. HIV-1 envelope DNA construct of EAC-I (A) and EAC-II (B). Complete sequence of envelopes (EAC-I and EAC-II) was cloned into pCDNA3.1.
(C). Comparison of the deduced amino acid sequences from EAC-I with codon-optimized HIV-1 JR-FL envelope. *, identity with the consensus sequences.
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Plasmid vaccines induced T cell proliferation response in
mice
CD4 T cells play a critical role in supporting both
humoral responses via expansion of antigen-stimulated B
cells and the cellular immune response via expansion of
CD8 cytotoxic T cells. One indication of CD4 helper cell
function is antigen-specific proliferation in the standard
LPA assay. The induction of antigen-specific Th cell re-
sponse to EAC-I, EAC-II, or envelope subtype B immuni-
zation was next examined, and the results are shown in Fig
5A. It is important to note that proliferation in response to
recombinant subtype B envelope antigen stimulation was
studied as envelope subtype A reagents are not available. As
shown in Fig. 5A, EAC-I, EAC-II, or envelope subtype B
vaccination induced a detectable Th cell proliferation re-
sponse as compared to the vector-immunized control ani-
mals. In this T cell assay EAC-I was more effective than
EAC-II and as high as the optimized envelope subtype B
construct, supporting a stronger induction of T-helper cells.
Induction of cellular response in vivo
To examine induction of the antigen-specific CTL re-
sponse, a typical 51Cr release assay was employed. We
measured CTL induction in mice immunized with EAC-I,
EAC-II, or the optimized envelope subtype B. Specific
target lysis is presented in Fig. 5B. Splenocytes from mice
immunized with EAC-I exhibited 29% killing and EAC-II
exhibited only 12.5% at an E/T ratio of 100:1. Vector-
Fig. 3. (A) Expression of HIV-1 Envelope protein. The env gene for EAC-I and EAC-II was cloned into a pCDNA3.1 expression vector. Expression of EAC-I
and EAC-II, following transfection. Seventy-two hours after transfection cells were harvested and 100 g of protein extract was analyzed by 15% SDS–PAGE
and immunoblotted with antienvelope (HIV-1 gp120) antibodies as described under Materials and methods. The arrow indicates the gp120 protein. (B and
C) Expression of env gene as a viral particle. Single-round replication kinetics of pseudovirus complemented with envelope. PBMCs (1  106) cells were
infected with env-complemented virions. Viral production after infection was monitored at regular 24-h intervals by measuring p24 level in the culture
supernatants (B). Human PBMCs were infected with pseudovirus complemented with envelope (EAC-I and EAC-II) packaged virus. After 96 h; samples were
collected and cells were stained with PE-conjugated p24gag antibody. The analysis was performed on a gated low forward scatter and cells were further
analyzed for the expression of p24 expression (C). pNL4-3 wt virus was used as a positive control and uninfected cells were used as mock. Both of the
experiments were repeated twice with similar results.
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immunized and envelope subtype B immunized exhibited 5
and 20%, respectively, at the same ratios. We observed
similar results in three separate studies. These results clearly
demonstrate that the EAC-I DNA construct induces strong
CTL responses comparable with improved DNA immuno-
gens.
Th1- and Th2-type cytokines enhances
The Th1 response is directly correlated with IFN- pro-
duction, which is important for activation of CD8 effector
T cells, which are intricately involved in antiviral T cell
mediated immune responses. In contrast, IL-4 plays a dom-
inant role in Th2 B cell mediated immune responses and can
inhibit the development of effector CD8 responses. There-
fore we next analyzed the production of Th1- and Th2-type
cytokines (IFN- and IL-4, respectively) induced by these
novel immunogens. We analyzed supernatant from stimu-
lated T cells as described under Materials and methods for
antigen-dependent cytokine elaboration. Immunization with
EAC-I or EAC-II significantly increased the level of HIV-1
antigen-specific elaborated IFN-. In this assay, EAC-I was
more effective than EAC-II but as effective as the envelope
subtype B. There was only a small effect on IL-4 release for
any construct showing the strong Th1 bias of these vectors
(Fig. 6) and the intramuscular plasmid approach in general.
Immune response by ELISpot analysis
Another, more quantitative measurement of Th1-type
CD8 T cell immunity is ELISpot analysis. We analyzed
CD8 T effector cells, which had been stimulated in vitro,
and tested them for IFN- production by an ELISpot assay.
Three injections of 100 g of the constructs were potent to
generate strong Th1 CD8 specific responses as detected in
a sensitive ELISpot assay. There was no significant reac-
tivity in this assay detected in vector-immunized mice.
However, 790 SFU per 1  106 splenocytes were seen in
EAC-I compared to 390 SFU per 106 splenocytes seen in
EAC-II, at the peak of immune response (Fig. 7A). Immune
responses were also compared in ELISpot with an opti-
mized JR-FL envelope subtype B vaccine plasmid (Fig.
Fig. 4. (A) Envelope-specific serum antibody was determined by Western blot analysis. Each immunobilized membrane strip was incubated with immune
sera from envelope subtype B, EAC-I, or EAC-II immunized mice sere from 1 week after second-boost immunized mice as indicated under Materials and
methods. Arrow indicates antienvelope expression. (B) Total IgG antibody titers in the sera of the immunized mice. Humoral immune response after
immunization with DNA construct expressing env, as shown by enzyme-linked immunosorbent assay (ELISA). Each group of mice (n  4) was immunized
with 100 g of envelope DNA. Pooled normal mouse sera (NMS) were used as a control. Mice were bled and equally pooled sera were diluted in blocking
buffer at a dilution of 1:100 and assayed as described under Materials and methods. Absorbance (OD) was measured at 405 nm. Each data point represents
averaged optical density (OD) values from two mice sera per group and values represent mean of ELISA titers obtained in three separate assays.
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7B). Again the EAC-I plasmid was a similar level driving
CD8 effector responses in this quantitative cellular assay.
We were interested in further characterizing the re-
sponses that were observed in the ELISpot assay. Accord-
ingly, ELISpot assays were carried out against a library of
peptides spanning subtype B. Thirty 15-mer peptides with
10 amino acid overlaps between them, which span residues
1–870 of the HIV-1 envelope (MN) protein (DAIDS,
NIAID, 2001), were used. We used pooled stimulators in a
matrix assay which facilitates epitope mapping as described
(Boyer et al., 1997). The MN library is the only envelope
library that was available; however, since the ELISpot re-
sults were already against the whole pool, we felt that this
mapping would likely reveal the cross-reactive epitopes
induced by the EAC-I and subtype B immunogens. IFN-
ELISpot analysis of splenocytes derived from the envelope-
vaccinated animals revealed several reactive pools in com-
mon between the subtype B and subtype A immunogen, as
well as some unique specificities (Fig. 8A). Not all peptides
were recognized in both envelope-vaccinated groups. Im-
portantly the envelope subtype B immunogen reacting
against its homologous library reacted to 17 peptide pools in
the mix and recognized HIGPGRAFYTTKNII as a domi-
nant epitope (Fig. 8B). This peptide overlaps completely
with the SYFPEITHI epitope-predicted RAFYTTKNI for
the BALB/C mouse H-2 loci (a database of MHC ligands
and peptide motifs (Ver. 1.0); Institute for Cell Biology,
Dept. of Immunology, BMI-Heidelberg, Germany) (Taka-
hashi et al., 1989). Surprisingly the subtype A, EAC-I-
immunized splenocytes recognized nine epitopes. Of these
only six were shared and surprisingly there were epitopes
that were induced specifically by the EAC- (subtype A)
immunogen alone. We observed that the NYNKRKRIHIG-
PGRA was a dominant epitope (Fig. 8C) induced by the
EAC-I vector. This peptide overlaps completely with the
SYFPEITHI epitope prediction YNKRKRIHI, for the
BALB/C mouse H-2 loci (Takeshita et al., 1985; Takahashi
et al., 1989).
Fig. 5. (A) T cell proliferation response to envelope. Splenocytes derived from envelope-immunized mice were pooled and used in proliferative assays. Mice
were immunized with 100 g of envelope DNA and 1 week after the second boost injection, mice were sacrificed and their spleen cells were pooled.
Recombinant gp120 (1 or 5 g/ml) was plated in each well to stimulate proliferation of T cell. After 3 days stimulation, cells were harvested and the counts
per minute were determined. Stimulation index was calculated as the level of radioactivity detected from the cells in media. Samples were assayed in
triplicate. This experiment was repeated twice with the same results. Values and bars represent means and SD. (B) Antigen-specific CTL responses following
injection with envelope genes. Mice were immunized intramuscularly with 100 g of each DNA. p815 cells (1  105/ml) were stimulated with peptide and
incubated for 16 h to stimulate the cells. The target cells were labeled with 51C for 1–2 h and used to incubate the stimulated splenocytes according to the
formula described under Materials and methods. To calculate specific lysis of targets, the percentage lysis of irrelevant targets was subtracted from the
percentage lysis of specific lysis. The experiments have been repeated twice, with similar results.
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Discussion
The estimated 57.9 million people who have been in-
fected with HIV since the pandemic began have, with a few
exceptions, acquired the virus by one of the three modes of
transmission: sexual, parenteral, or mother to child. The
African continent is the hardest hit, being the home to an
estimated 70% of the adults and 80% of the children living
with HIV (Cohen, 2000a,c; Morison, 2001). Sub-Saharan
Africa is devastated by the HIV/AIDS epidemic. The situ-
ation is complicated by the unique HIV subtype diversity
observed in Africa. While subtype B predominates in the
U.S. and Europe, the east African epidemic is predomi-
nately subtype A and D virus, and while the west Africa
pandemics is predominately A and combination A/G viruses
(Kanki et al., 1999; Cohen, 2000a,b; Gaschen et al., 2002),
South Africa is plagued subtype C. It is clearly important for
HIV vaccine developers to understand the immune differ-
ences presented by different subtype immunogens (Ndung’u
and Lu, 2001). One technical issue limiting such under-
Fig. 6. Expression of cytokines by stimulated effector cells. Production of Th1/Th2 cytokines by stimulated effector cells. Supernatants from peptide-
stimulated T cells were collected at day 5 and tested for their cytokine profile using ELISA kits specific for IFN- (A) and IL-4 (B). These experiments have
been repeated twice, with similar results. Values and bars represent the mean cytokine concentration and SD.
Fig. 7. Induction of intracellular IFN- in vaccinated splenocytes. Secretion of specific IFN- production in EAC-I- and EAC-II-immunized splenocytes (A)
and comparison of EAC-I with subtype B (JR-FL) immunized mice (B) 1 week after the second boost was assessed using an ELISpot assay as described
under Materials and methods.
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standing has been determining the best way to express the
envelope antigen to study its potential as a vaccine vector.
The specific nature of the adaptive immune responses
makes it difficult to use one unique viral sequence as a
vaccine to induce immunity against a highly diverse virus
such as HIV-1 (Cole et al., 1997; Letvin, 1998; Gandhi and
Walker, 2002; Barouch et al., 2002; Moore et al., 2002). To
test and compare the effectiveness of multiple HIV subtype
immunogens, it is necessary to develop several different
envelope constructs for comparative studies. However, the
further requirement to also develop rev-independent vectors
through codon changes (Tabernero et al., 1996; Cole et al.,
1997; Muthumani et al., 2002a) significantly increases the
cost of these vectors and slows progress in this area. We
Fig. 8. Characterization of envelope-specific dominant epitopes. (A) Secretion of IFN- by splenocytes from HIV-1 envelope-specific immune responses
using the 15-mer peptides. Splenocytes were cultured overnight with HIV-1 MN envelope peptide pools. After addition of the peptide, 1  106/well
splenocytes were immediately transferred to the wells of 96-well ELISpot plate in two replicate wells. Production of IFN- by CD8 cells were detected
after 24 h of incubation. The results are expressed as the number of IFN- secreting cells/106 spleen cells (mean  SD for three mice per group) after
subtracting values without peptide stimulation. Similar results were obtained in two separate experiments. (B and C) Immunodominant-positive peptide pool
sequences identified each envelope-immunized group as indicated.
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sought a quicker method to develop envelope-based immu-
nogens for study. In this regard it has been reported that the
Mason–Pfizer virus cis-acting transcription element can by-
pass rev restriction of rev-dependent constructs (Paca et al.,
2000; Wodrich et al., 2001; von Gegerfelt et al., 2002). Both
codon optimization and CTE are supposed to increase ex-
pression. Codon optimization has the two following positive
effects on protein production: (i) it facilitates abundant
trans-increasing translation and (ii) it removes the RRE thus
destroying rev dependence and nuclear retention. In this
regard CTE works through a different mechanism, by bind-
ing directly to the host cell mRNA exportation machinery.
Accordingly CTE is a positive element that facilitates
mRNA transportation.
The cis-acting transactivation element derived from Ma-
son–Pfizer monkey virus is able to mediate export of un-
spliced and partially spliced RNA molecules into the cyto-
plasm. This mechanism involves binding of CTE to as yet
undefined host-encoded nuclear proteins and is different
from rev-mediated RNA export (Rizvi et al., 1996; Pas-
quinelli et al., 1997; Saavedra et al., 1997). It is not clear if
the rev pathway and CTE pathway would complement each
other. To test this hypothesis, we compared envelope con-
structs in expression studies. Both EAC-I and EAC-II con-
structs have a CTE at their 3 end. However, the EAC-I
insert has both rev and env as functional ORFs while EAC-
II has only the env ORF’. By immunoblot assay EAC-I
expression is higher than that of EAC-II and perhaps that of
a rev-independent subtype B construct. This result was
supported by pseudotype expression assay (Figs. 3B and C),
where again EAC-I exhibited the greatest ability to func-
tionally complement a viral particle and deliver the viral
particle in vitro.
Expression in vitro does not alone indicate that the con-
structs will be more effective as a plasmid vaccine. How-
ever subsequent immunization assays supported the initial
expression results. For example EAC-I preferentially in-
duced a higher antibody titer than the CTE driven vector
(EAC-II) or the optimized envelope subtype B vector. These
results are more impressive when it is considered that we
did not have access to subtype A reagents; accordingly the
responses are analyzed on envelope subtype B reagents.
Such assays should intrinsically favor the envelope subtype
B vaccine. Yet, antibody responses induced by EAC-I came
up faster and remained strong throughout the study. We
performed analysis of cellular immune induction as well
EAC-I plasmid injection induced a small level of IL-4.
However, importantly IFN- was induced to a great extent
by the EAC-I plasmid vaccines. LPA responses were next
examined as a further marker of T cell help. The EAC-I
construct was more effective than CTE only (EAC-II) con-
structs. In fact the stimulation index (SIs) observed with
EAC-I was consistently among the highest envelope-based
SIs we have generated to date. Examination of CTL and
ELISpot responses again illustrated the strength of the dual
export construct. We observed that the subtype A induced
immunodominant response in the BALB/C mice was di-
rected at YNKRKRIHI. In contrast as previously reported
the envelope subtype B CD8 dominant response was di-
rected against the RAFYTTKNI (Takeshita et al., 1985;
Takahashi et al., 1989). These epitopes are similar in both
the subtype B and the subtype A constructs, but they are not
identical. The anchor peptides contain small changes in their
amino acids which may be responsible for the different
epitope recognition of these immunogens. However, it is
also likely that differences in other regions of the envelope
protein which change processing at the TAP system could
also be important. This observation highlights the contribu-
tion of small epitope changes to observed T cell responses
and underscores the importance of comparative immunogen
study to complement computer prediction analysis.
In summary, we have constructed a subtype A envelope
plasmid (EAC-I), which contains a combination of CTE and
rev to drive envelope expression by dual export pathways.
This construct induced strong humoral and cell-mediated
immune responses in BALB/C mice, suggesting a simple
and rapid approach to producing HIV subtype immunogens
for examination in vaccine or immunogenicity or pathogen-
esis studies and may represent a reasonable alternative to
condon optimization strategies.
Materials and methods
Mice
Female 4- to 6-week-old BALB/C mice (Harlan Spra-
gue–Dawley Inc., Indianapolis, IN) were housed at the Uni-
versity of Pennsylvania according to the guidelines of the
National Institutes of Health and IACUC-approved proto-
cols.
Construction of subtype A envelope plasmids
HIV-1 subtype A containing plasmids in the prokaryotic
cloning vector pCRII (Invitrogen, USA) were obtained from
the Walter Reed Institute, MD. For cloning the sequence
converging from 5 of rev to the 3 end of env and the
envelope sequence were amplified by PCR. The primers
used were for EAC-1 envelope covering rev and the CTE
(5-TTAGCTAGCCACCATGGCAGGAAGAAGCGGAG-
ACGCCG-3 and 5-ACGCGTAGCAAACAGAGGCCA-
AGACA-3) and the sequence of EAC-II envelope covering
env (5-TTAGCTAGCCA CCATGGCAGGAAGAAG-
CGGAGACGCCG-3 and 5-CCAGGATCCTTAT AG-
CAAAGCCC TTTCGAGACC-3). The PCR fragment of
3.7 kb (EAC-I) and 2.8 kb (EAC-II) was gel-purified with
Gel Purification Kit (Qiagen, USA), digested with Nhe1/
EcoRV and Nhe1/BamH1 (New England Biolabs, USA),
and cloned into a eukaryotic expression vector pCDNA3.1
(Invitrogen). The resultant plasmid EAC-I has both rev and
CTE and EAC-II has only the CTE, and these plasmids
143K. Muthumani et al. / Virology 314 (2003) 134–146
therefore are confirmed by sequencing. The quality and
quantity of the purified plasmid DNA were tested by digest-
ing the vectors with the specific endonucleases followed by
electrophoresis. Codon-optimized envelope subtype B (JR-
FL) DNA was used in all experiments as a positive and
specific control.
Envelope expression
In vitro expression
After construction, EAC-I and EAC-II expression plas-
mids were tested for expression. Expression plasmids were
transfected in RD cells (1  106) using DOTAP Liposomal
transfection method (BM GmbH, Germany). Seventy-two
hours after transfection, cells were washed in warm PBS
and lysed in 500 l of lysis buffer (20 mM Tris, pH 7.5/150
mM NaCl/ 1% Triton/1 mM EDTA/30 mM NaF/2 mM
sodium pyrophosphate/10 g/ml aprotinin/10 g/ml leu-
peptin). The total protein lysates (100 g) were fractioned
on SDS–PAGE (15%) and transferred to a PVDF membrane
(Bio-Rad, Hercules, CA). Immunoblot analyses were per-
formed with mouse anti-gp120 antiserum as described
(Muthumani et al., 2002) and visualized with horseradish
peroxidase coupled goat anti-rabbit IgG using an ECL de-
tection system (Amersham Pharmacia Biotech, Piscataway,
NJ) for visualization.
Viral production and infection assay
HIV-1 pseudotype particles were generated by cotrans-
fection with the developed env constructs and a pNL4-3/E
backbone (He et al., 1995) by a DOTAP Liposomal trans-
fection method (BM GmbH) with RD cells. Constructs that
encode the HIV-1 envelope were tested for viral comple-
mentation in a single-round infectivity assay. The viral titers
were determined by infection of the human T cell line Jurkat
and p24gag antigen was measured by capture ELISA, using
a p24 ELISA kit (Coulter, FL, USA) (Muthumani et al.,
2002b).
We used a concentration of 100 TCID50/106 cells/ml of
viral particle to infect PBMC isolated from HIV-negative
donors stimulated with PHA (5 g/ml). For FACS analysis,
96 h after infection, PBMC were stained with anti-p24gag
antibody (KC57-PE, Coulter) and analyzed by flow for
p24gag-positive cells. Cells were washed with PBS and fixed
with 2% paraformaldehyde and analyzed by a fluorescence
activated cell sorter (Beckon–Dickinson, CA). Data were
analyzed using CELL Quest program (Beckon–Dickinson)
(Muthumani et al., 2002b).
Immunization of mice and serum sample collection
Female BALB/C (H-2d) mice, 6–8 weeks of age, as
groups of four mice were used for vaccinations. We utilized
a facilitated DNA inoculation protocol (Chattergoon et al.,
1998). Specifically, the quadriceps muscles of BALB/C
mice were injected with 100 g of envelope construct
formulated in 100 l of 0.25% bupivacaine–HCl in PBS
(Sigma, MO) using a 27-gauge needle. Mice were given a
first injection followed by a boost (first boost) 2 weeks later.
Two weeks after the second injection, half of the mice in
each group were sacrificed for their spleens, and the remain-
ing mice were given a third injection (second boost) with
the appropriate DNA construct. Blood was collected by
retroorbital puncture before each injection and sera were
frozen at 20°C until analysis. At 1 week after second
boost injection, the mice were sacrificed; the spleens were
harvested, and the lymphocytes were isolated and analyzed
for specific immune responses.
Detection of antienvelope antibodies
The serum antibody reactivity to recombinant HIV-1
envelope protein was analyzed by ELISA as previously
described (Kim et al., 1997). Briefly, 50 l of recombinant
gp120 diluted in PBS to 10 g/ml was adsorbed onto
microliter wells overnight at 4°C as described elsewhere
(Kim et al., 1997). Plates were than rinsed with washing
buffer (0.45% NaCl in dH2O containing 0.05% Tween 20)
and blocked with blocking buffer (5% nonfat dry milk in
PBS with 1% bovine serum albumin (BSA) and 0.05%
Tween 20) for 2 h at 37°C. Fifty micro liters of serum
samples (1/100 in PBS) (1 week after second boost) was
then diluted in buffer and incubated in triplicate in recom-
binant protein-coated wells for 1 h at 37°C, washed, and
then incubated for 1 h at 37°C with a goat anti-mouse
IgG-HRP (Sigma) diluted in dilution buffer. The plates
were washed and developed with 3355 TMB buffer and
the plates were read on a Dynatech MR5000 plate reader
with the OD of 405 nm. The ELISA titers were determined
as the reverse of the highest serum dilution showing the
same OD value as sera of naive mice. Additionally, a
standard Western blot assay was employed as previously
described (Muthumani et al., 2002b).
T helper cell proliferation assay
Cell proliferation assays were performed as previously
described (Chattergoon et al., 1998). Briefly, isolated
spleenic cells (1 week after second boost) were resuspended
at a concentration of 1  106 cells/ml. A 100 l aliquot
containing 1  105 cells was added to each well of a
96-well microliter flat-bottom plate. The HIV-1 recombi-
nant gp120 protein was added to the wells in triplicate at
final concentrations of either 1 g or 5 g/ml. The cells
were incubated at 37°C in 5% CO2 for 2 days. 3H (1 Ci)
was added to each well, and the cells were incubated for 12
to 18 h at 37°C. The plate was harvested, and the amount of
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incorporated tritiated thymidine was measured in a Beta
plate reader (Wallac, Finland).
Cytotoxic T lymphocyte (CTL) assay
A typical 51Cr release bulk CTL assay was employed to
study the antigen-specific CTL response. A standard 51Cr
release assay was performed (Kim et al., 1997). The assay
was done with in vitro effector stimulation, in which the
effectors were stimulated with a pool of envelope-specific
peptides (EAC-I, GYSPLSFQTL; EAC-II, NYTQIIYNLI)
using the strategy described by HLA peptide motif analysis
at http://bimas.dcrt.nih.gov/molbio/hla_bind/ at a final con-
centration of 10 g/ml for 4 days in culture media, added to
wells in triplicate. Peptide-treated targets were prepared by
incubating p815 cells with 10 g/ml of the envelope-spe-
cific peptide pool. The target cells were labeled with 100
Ci/ml Na2 51CrO4 for 2 h and incubated with the stimu-
lated effector splenocytes for 6 h at 37°C. CTL lysis activity
was determined at effector:target (E:T) ratios ranging from
100:1 to 12.5:1. Percentage of specific lysis was determined
as described previously (Kim et al., 1997), using the for-
mula: 100  [(experimental release  spontaneous release/
maximum release  spontaneous release)]. Maximum re-
lease was determined by lysis of target cells in 1% Triton
-100 containing medium.
Evaluation of IL-4 and IFN- levels in supernatants of
immunized splenocytes
Culture supernatants from stimulated effector T cells
were collected at day 5 and tested for expression using
commercial cytokine ELISA kits for IL-4 and IFN- (Bio-
source Intl., CA, USA) by adding the extracellular fluids to
the cytokine-specific ELISA plates and developing the kits,
as described by the manufacturer.
Overlapping peptides for the ELISpot assay
Complete sets HIV-1 MN Envelope (15-mer) peptides
were provided by the NIH AIDS Research and Reference
Reagent Program, MD, USA. After addition of the peptide
mixture, 1  106/well splenocytes were immediately trans-
ferred to the wells of a 96-well ELISpot plate in two rep-
licate wells that were previously coated with 10 g/ml of
anti- IFN- monoclonal antibody and blocked with phos-
phate-buffered saline containing 5% bovine serum albumin
prior to the addition of the peptide-treated cells. Approxi-
mately 1  106 stimulated splenocytes were added in du-
plicate to each well and ELISpot was performed after 6 h
incubation by using the ELISpot kit (R&D Systems, MN,
USA) as described by manufacturer’s instruction. The blue-
black-colored precipitated spots were counted by an auto-
mated ELISpot reader system (CTL, OH).
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